C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/13 (2006.01) A61K 31/7088 (2006.01) A61K 39/395 (2006.01) A61K 48/00 (2006.01) A61P 31/14 (2006.01) A61P 31/18 (2006.01) C07K 14/73 (2006.01) C07K 16/10 (2006.01) C12Q 1/70 (2006.01) G01N 33/569 (2006.01)
Patent
CA 2463931
The present invention features antibodies and antibody fragments that specifically bind a CD4-inducible HIV gp120 epitope that is enhanced by binding a co-receptor for HIV, such as CCR5 or CXCR4, and pharmaceutical compositions comprising the antibodies or antibody fragments. The invention also features nucleic acids encoding the antibodies or antibody fragments, pharmaceutical compositions comprising the nucleic acids encoding the antibodies or antibody fragments, vectors comprising the nucleic acids, and cells comprising the vectors. The invention further features methods of identifying antibodies or antibody fragments with broadly neutralizing activity against HIV. The invention also features methods of inhibiting HIV entry into cells and methods of inhibiting replication of HIV in mammals, using the antibodies and nucleic acids of the invention.
L'invention concerne des anticorps et des fragments d'anticorps fixant spécifiquement un épitope sur gp120 du VIH inductible par CD4 amélioré par fixation d'un co-récepteur de VIH, tel que CCR5 ou CXCR4, et des compositions pharmaceutiques comprenant lesdits anticorps ou fragments d'anticorps. L'invention concerne également des acides nucléiques codant les anticorps ou les fragments d'anticorps, des compositions pharmaceutiques comprenant les acides nucléiques codant les anticorps ou les fragments d'anticorps, des vecteurs comprenant les acides nucléiques, et des cellules comprenant les vecteurs. L'invention concerne en outre des méthodes d'identification des anticorps ou des fragments d'anticorps possédant sensiblement une activité de neutralisation du VIH. L'invention concerne enfin des méthodes d'inhibition d'entrée du VIH dans les cellules et des méthodes d'inhibition de réplication du VIH chez les mammifères à l'aide des anticorps et des acides nucléiques de l'invention.
Burton Dennis
Dimitrov Dimiter S.
Moulard Maxime
Phogat Sanjay K.
Shu Yuuei
Department Of Health And Human Services The Government Of The United States Of America Represented By Th
Ridout & Maybee Llp
The Scripps Research Institute
LandOfFree
Broadly cross-reactive neutralizing antibodies against human... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Broadly cross-reactive neutralizing antibodies against human..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Broadly cross-reactive neutralizing antibodies against human... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1481414